Pfizer's stock has declined nearly 20% over five years, pushing its dividend yield to around 6%. Despite this, the company continues to pay a steady $0.43 quarterly dividend, supported by earnings that cover the payout but with tight cash flow margins. CEO Albert Bourla has committed to maintaining the dividend through upcoming challenges, including a $1.5 billion loss-of-exclusivity impact in 2026, though significant dividend hikes are unlikely until growth resumes. Investors face a mixed picture: an attractive yield driven by price weakness, solid earnings coverage, but limited buybacks and tight cash flow.
Rivian's CFO Claire McDonough is stepping down, but unlike recent CFO changes at AT&T, Caterpillar, and Pfizer that sparked double-digit stock rallies, Rivian's shares fell slightly. The key difference is Rivian has only named an interim CFO and is s...
Pfizer and Starbucks both raised their outlooks recently, but Pfizer's recovery is more advanced and income-focused investors benefit from its higher dividend yield of 6.2% compared to Starbucks' 2.3%. Pfizer’s earnings growth is already evident, whi...
